EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Optimizing RhD Immune Globulin Use in Pregnancy

Elizabeth Miller, Lana El-Kassis, George Saade, Rebecca Horgan iD

American Journal of Perinatology · 01.10.2025 · 42 (14) · 1928-1934

DOI: 10.1055/a-2550-5130 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Perinatology, erschienen am 01.10.2025. Verfasst von Elizabeth Miller und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Macon and Joan Brock Virginia Health Sciences, Old Dominion University, Norfolk, Virginia. Hauptthemen laut MEDLINE: Rho(D) Immune Globulin, Rh Isoimmunization, Erythroblastosis, Fetal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global shortage of RhD immune globulin, formally acknowledged by the Food and Drug Administration in 2023, is ongoing but has improved in recent months. In response, the American College of Obstetricians and Gynecologists (ACOG) issued guidance in March 2024 on alternative strategies to conserve RhD immune globulin supplies. Our objective is to evaluate strategies for optimizing RhD immune globulin use in pregnancy amidst a global shortage. This clinical opinion reviews guidance on strategies to conserve RhD immune globulin. These include targeted administration based on non-invasive fetal RhD genotyping using cell-free DNA (cfDNA), the use of alternative RhD immune globulin products, and selective withholding of prophylaxis in early pregnancy loss under 12 weeks' gestation. ACOG guidance on the administration of RhD immune globulin in pregnancy differs from many countries worldwide, as well as the World Health Organization and the American Society of Family Planning. Targeted administration and the use of non-invasive cell-free DNA (cfDNA) testing for fetal RhD status have shown promising accuracy and reliability in studies across multiple countries, leading to reduced unnecessary prophylaxis and potential cost savings. Additionally, withholding RhD immune globulin in select early pregnancy losses could further conserve resources without increasing alloimmunization risk. This review underscores the need for evidence-based approaches to manage limited RhD immune globulin supplies effectively and suggests that targeted prophylaxis could benefit both patient outcomes and healthcare resource allocation in the face of global shortages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rho(D) Immune GlobulinRh IsoimmunizationErythroblastosis, FetalHumansPregnancyFemaleCell-Free Nucleic AcidsPractice Guidelines as TopicRh-Hr Blood-Group System

Substanzen

Rho(D) Immune GlobulinCell-Free Nucleic AcidsRh-Hr Blood-Group System

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Macon and Joan Brock Virginia Health Sciences, Old Dominion University, Norfolk, Virginia.

ORCID-Profile: Rebecca Horgan

Zitieren

APA

Miller, E., El-Kassis, L., Saade, G., & Horgan, R. (2025). Optimizing RhD Immune Globulin Use in Pregnancy. American Journal of Perinatology, 42(14), 1928-1934. https://doi.org/10.1055/a-2550-5130

Vancouver

Miller E, El-Kassis L, Saade G, Horgan R. Optimizing RhD Immune Globulin Use in Pregnancy. American Journal of Perinatology. 2025;42(14):1928-1934. doi:10.1055/a-2550-5130

BibTeX
@article{Miller2025,
  author = {Miller, Elizabeth and El-Kassis, Lana and Saade, George and Horgan, Rebecca},
  title = {Optimizing RhD Immune Globulin Use in Pregnancy},
  journal = {American Journal of Perinatology},
  year = {2025},
  volume = {42},
  number = {14},
  pages = {1928--1934},
  doi = {10.1055/a-2550-5130}
}
Kostenlos starten →